+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice



Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice



Acta Reumatologica Portuguesa 36(2): 110-118



Reactivation of infection with hepatitis B virus (HBV) is a potentially serious complication of immunosuppression, which can be identified and efficiently prevented. There have been an increasing number of cases of HBV reactivation in patients receiving immunosuppression in the context of rheumatic diseases such as rheumatoid arthritis or systemic lupus erythematosus. The recommendations in this area should be individualized taking into account two aspects: immunosuppressive regimens used (high or low risk of reactivation) and the different stages of HBV infection: chronic hepatitis B, inactive HBV carrier, occult hepatitis B infection defined by HB surface antigen (HBsAg) negative and antibody anti-HB core (anti-HBc) positive. In patients with rheumatic diseases that will start high-risk immunosuppressive drugs, we propose a universal screening with serological tests for hepatitis B (HBsAg, anti-HBs and anti-HBc). Patients with chronic hepatitis B (HBsAg positive, HBV DNA ≥ 2000 IU/ml, elevated ALT) should initiate antiviral therapy. Inactive HBV carriers (HBsAg positive, HBV DNA <2000 IU / ml, normal aminotransferases) exposed to high risk immunosuppressive therapy should undergo prophylaxis of HBV reactivation. Prophylaxis should be started 2 to 4 weeks before the beginning of immunosuppressive therapy and maintained for at least 6 to 12 months after its suspension. It is recommended to use entecavir or tenofovir as first line antiviral agents. In inactive HBsAg carriers under low-risk immunosuppressive therapy and patients with HBsAg negative/anti-HBc positive (HBV infection in the past), the strategy should be monitoring of viral reactivation with aminotransferases and HBV DNA determination in every 6 months.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055232382

Download citation: RISBibTeXText

PMID: 21841730


Related references

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Annals of the Rheumatic Diseases 65(8): 983-989, 2006

Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases?. Journal of Rheumatology 39(6): 1292-3; Author Reply 1293, 2012

Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review. Clinical Rheumatology 33(4): 577-586, 2015

Prophylaxis of reactivation of hepatitis B and hepatitis C virus infection in immunosuppressive therapy. Ugeskrift for Laeger 181(6), 2019

SAT0140Prevalence of Reactivation of Hepatitis B Virus (HBV) in Patients with Resolved Hbv Hepatitis on Immunosuppressive Therapy for Rheumatic Disease: Multicentre Prospective Observational Study in Japan. Annals of the Rheumatic Diseases 75(Suppl 2): 715.1-715, 2016

Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Current Opinion in Rheumatology 20(4): 443-449, 2008

Mo1030 Efficacy of Antiviral Therapy in Reactivation Prophylaxis in Patients With Hepatitis B (Hbv) Infection Treated With Different Immunosuppressive Agents. Gastroenterology 148(4): S-1068, 2015

Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. Journal of Rheumatology 38(10): 2209-2214, 2012

Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Annals of the Rheumatic Diseases 76(6): 1051-1056, 2016

Pneumocystis carinii pneumonia prophylaxis in patients with rheumatic diseases undergoing immunosuppressive therapy: prealence and associated features. Journal of Clinical Rheumatology 6(2): 94-101, 2000

Su1015 Entecavir (Ent) or Tenofovir (Tnf) Are Effective in Hbv Reactivation Prophylaxis and Treatment After Lamivudine (Lam) Failure in Patients With Malignant Diseases Receiving Immunosuppressive Therapy. Gastroenterology 146(5): S-963, 2014

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Research and Therapy 20(1): 246, 2018

Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy. Gut and Liver 11(6): 870-877, 2017

Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World Journal of Hepatology 7(3): 539-547, 2015

Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. International Journal of Rheumatic Diseases 16(5): 527-531, 2014